It May Be Time for a Class-Action Investigation. Peptide Businesses Unfairly Cut Off.
Across the peptide, compounding, telehealth, wellness, and research industries, businesses are reporting a troubling pattern: terminated merchant accounts, frozen funds, rejected applications, excessive reserves, and sudden restrictions tied to peptide-related products.
These actions can financially cripple a lawful business—sometimes without a meaningful explanation, individualized review, or opportunity to appeal.
The time has come to determine whether these were independent risk decisions or part of a coordinated effort to eliminate competition.
When Private Companies Control Access to the Marketplace
Visa and Mastercard are not government regulators, yet access to their payment networks is essential for most modern businesses.
When card-brand rules or enforcement pressure cause banks and payment processors to terminate entire categories of merchants, those decisions can determine which businesses survive and which are effectively removed from the marketplace.
That power deserves scrutiny—especially if restrictions were influenced by a pharmaceutical company seeking to protect its commercial interests.
Eli Lilly has publicly called upon payment companies and online platforms to take action against sellers of certain peptide products. Lilly has also pursued litigation against businesses it alleges are selling unauthorized or unlawful products.
Lilly has every right to protect legitimate patents, trademarks, and patients from counterfeit or unsafe drugs. However, those rights should not provide a blank check to pressure payment networks into indiscriminately cutting off lawful businesses, research suppliers, medical providers, pharmacies, or companies selling products outside the scope of Lilly’s enforceable rights.
Allegations are not court judgments, and private corporations should not be permitted to replace due process with financial blacklisting.
The Questions That Must Be Answered
Affected businesses deserve to know:
• Did Eli Lilly pressure Visa, Mastercard, acquiring banks, or payment processors to restrict peptide-related businesses?
• Were lawful merchants grouped together with companies accused of illegal activity?
• Were merchants terminated without an individualized compliance review?
• Were funds frozen or reserves imposed without adequate justification?
• Did card-brand penalties discourage processors from serving otherwise lawful businesses?
• Were payment restrictions used to suppress competition or strengthen Lilly’s control over the market?
• Were merchants given clear notice of the rule they allegedly violated and a meaningful opportunity to appeal?
• Did the companies involved coordinate policies, enforcement efforts, or merchant-identification information?
These questions do not establish liability by themselves. They are reasons for qualified attorneys and regulators to investigate.
Potential Grounds for Legal Review
Depending on the evidence, contracts, products involved, and circumstances of each termination, attorneys may examine whether the conduct could support claims involving:
• Anticompetitive conduct
• Unfair competition
• Tortious interference with business relationships
• Unfair or deceptive trade practices
• Breach of contract
• Improper withholding of merchant funds
• Coordinated market exclusion
• Other violations of federal or state law
No claim should be assumed to be viable until independent legal counsel has reviewed the facts. Arbitration provisions, card-network contracts, FDA rules, product labeling, patents, and differences among affected businesses could all influence whether a class action or another form of litigation is appropriate.
We Are Calling on Affected Businesses to Come Forward
2nd Amendment Processing is seeking information from peptide companies, compounding pharmacies, medical clinics, telehealth providers, research suppliers, payment professionals, and other businesses that have experienced:
• Merchant-account termination or suspension
• Rejection specifically connected to peptide products
• Frozen processing funds
• Excessive or unexpected reserves
• Sudden restrictions after previously being approved
• Notices referencing Visa, Mastercard, Eli Lilly, GLP-1 products, tirzepatide, retatrutide, or related peptides
• Processor warnings concerning card-brand fines or penalties
• Lost revenue caused by an inability to accept card payments
The purpose of this effort is to identify patterns, preserve evidence, and determine whether sufficient grounds exist to present the matter to qualified class-action and antitrust counsel.
Preserve Your Records
If your company has been affected, do not delete relevant communications or documents. Preserve:
• Merchant-processing agreements
• Termination and suspension notices
• Emails from processors, banks, gateways, or card brands
• Reserve and fund-hold notices
• Application rejection messages
• Compliance questionnaires
• Product descriptions and website screenshots
• Laboratory reports and certificates of analysis
• Legal opinions or compliance documentation
• Records showing lost sales, refunds, chargebacks, or other damages
• Communications mentioning Eli Lilly or specific peptide products
A clear documentary record may be essential to determining what happened and whether the affected businesses share legally similar claims.
This Is About Due Process and Fair Competition
This effort is not about protecting counterfeiters, unsafe products, deceptive marketing, or companies that intentionally violate the law.
It is about defending lawful American businesses from being financially eliminated through private pressure, undisclosed rules, or indiscriminate enforcement.
Patent rights should be enforced in court. Health and drug laws should be enforced by the appropriate regulators. Payment networks should not become private enforcement arms for the commercial interests of the most powerful market participant.
If evidence shows that lawful businesses were collectively denied payment access to suppress competition, the companies responsible should be held accountable.
Have You Been Affected?
If your business has lost payment processing, had funds frozen, faced an excessive reserve, or received a peptide-related warning, we want to hear what happened.
Contact 2nd Amendment Processing and provide a brief description of:
1. Your type of business
2. The products involved
3. The processor or bank involved
4. The action taken against your account
5. The date it occurred
6. Any financial losses you suffered
7. Whether Eli Lilly, Visa, Mastercard, or a specific peptide was mentioned
Your information may help establish whether these incidents were isolated decisions or evidence of a broader pattern requiring legal action.
One business can be silenced. An entire industry cannot be ignored.
Important Notice
2nd Amendment Processing is not a law firm and is not providing legal advice or promising that litigation will be filed. Submitting information does not create an attorney-client relationship, guarantee confidentiality, establish eligibility for a class action, or guarantee any recovery. Information gathered may be provided to independent legal counsel for evaluation only with appropriate authorization. Businesses should consult their own qualified attorney concerning their individual circumstances.
Thomas TroyerCEO | 2nd Amendment Processing Veteran Owned Business 833-755-6696 | 517-755-6696 |
Comments